Cytokinetics (NASDAQ:CYTK) Trading Down 7.7% After Earnings Miss

Cytokinetics, Incorporated (NASDAQ:CYTK) fell 7.7% on Wednesday following a weaker than expected earnings announcement. The stock traded as low as $64.51 and last traded at $64.6990. 667,422 shares changed hands during trading, a decline of 61% from the average session volume of 1,698,679 shares. The stock had previously closed at $70.10.

The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.02). The firm had revenue of $17.76 million during the quarter, compared to analyst estimates of $8.02 million. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($1.26) EPS.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: MYQORZO approved in U.S., China and Europe and U.S. launch is already underway; company reiterated 2026 catalysts (including ACACIA‑HCM topline in Q2) and disclosed substantial cash reserves. This is a material commercial and pipeline positive for future revenue. Cytokinetics Reports Fourth Quarter 2025 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised price targets and kept bullish ratings (Citizens JMP to $96 market‑outperform; Needham to $85 buy), signaling continued analyst conviction and upside vs. the current price. Benzinga coverage
• Positive Sentiment: Company highlighted a strong cash position (~$1.2B) to fund commercialization and upcoming trials — a balance‑sheet cushion that supports execution into 2026 catalysts. Zacks: CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans
• Neutral Sentiment: Revenue beat estimates ($17.7M reported vs. ~$8M consensus), showing commercial pickup or other revenue sources, but revenue alone did not offset rising expenses this quarter. MarketBeat: Earnings details
• Neutral Sentiment: Full earnings call and transcripts are available for investors wanting details on expense drivers, launch timing and trial expectations. Seeking Alpha: Q4 2025 earnings call transcript InsiderMonkey transcript
• Negative Sentiment: EPS missed marginally ($‑1.50 vs. $‑1.48 expected) and the loss widened year‑over‑year as expenses rose, which likely triggered near‑term selling despite the revenue beat and approvals. Zacks: Q4 Loss, Beats Revenue Estimates

Analyst Ratings Changes

A number of brokerages have recently issued reports on CYTK. Citigroup reaffirmed a “market outperform” rating on shares of Cytokinetics in a research report on Monday, December 22nd. Needham & Company LLC lifted their price target on shares of Cytokinetics from $84.00 to $85.00 and gave the stock a “buy” rating in a report on Wednesday. Jefferies Financial Group reiterated a “buy” rating and set a $90.00 price objective on shares of Cytokinetics in a report on Friday, January 9th. Citizens Jmp boosted their target price on Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a research note on Wednesday. Finally, Truist Financial upped their target price on Cytokinetics from $84.00 to $92.00 and gave the company a “buy” rating in a research report on Tuesday, February 3rd. Sixteen equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cytokinetics currently has an average rating of “Moderate Buy” and an average target price of $88.78.

Insider Buying and Selling at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 2,200 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total value of $134,728.00. Following the sale, the executive vice president owned 138,552 shares in the company, valued at $8,484,924.48. This represents a 1.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Wendell Wierenga sold 20,000 shares of the stock in a transaction that occurred on Monday, December 22nd. The stock was sold at an average price of $66.14, for a total transaction of $1,322,800.00. Following the completion of the transaction, the director owned 32,444 shares in the company, valued at approximately $2,145,846.16. This trade represents a 38.14% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 151,385 shares of company stock worth $9,817,158. 2.70% of the stock is currently owned by insiders.

Institutional Trading of Cytokinetics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in Cytokinetics by 1.6% during the fourth quarter. Vanguard Group Inc. now owns 12,048,131 shares of the biopharmaceutical company’s stock valued at $765,538,000 after purchasing an additional 191,336 shares during the period. State Street Corp lifted its holdings in shares of Cytokinetics by 3.7% in the 4th quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after buying an additional 207,961 shares during the period. Deep Track Capital LP boosted its stake in shares of Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock worth $236,328,000 after buying an additional 650,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Cytokinetics by 0.5% in the fourth quarter. Geode Capital Management LLC now owns 3,056,017 shares of the biopharmaceutical company’s stock worth $194,214,000 after buying an additional 15,815 shares during the last quarter. Finally, Vestal Point Capital LP grew its holdings in Cytokinetics by 14.8% during the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock worth $98,294,000 after acquiring an additional 384,469 shares during the period.

Cytokinetics Stock Down 10.3%

The company has a market capitalization of $7.69 billion, a PE ratio of -9.63 and a beta of 0.54. The firm has a 50-day moving average of $64.21 and a two-hundred day moving average of $58.35.

About Cytokinetics

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.